Company’s 36-month beta value is 0.82.Analysts have differing opinions on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for AGIO is 54.74M, and currently, short sellers hold a 12.16% ratio of that floaft. The average trading volume of AGIO on April 26, 2024 was 760.63K shares.
AGIO) stock’s latest price update
Agios Pharmaceuticals Inc (NASDAQ: AGIO) has seen a decline in its stock price by 0.00 in relation to its previous close of 31.67. However, the company has experienced a 7.61% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-05 that CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024, at 10:00 a.m.
AGIO’s Market Performance
AGIO’s stock has risen by 7.61% in the past week, with a monthly rise of 8.98% and a quarterly rise of 35.23%. The volatility ratio for the week is 5.02% while the volatility levels for the last 30 days are 4.03% for Agios Pharmaceuticals Inc The simple moving average for the last 20 days is 7.89% for AGIO stock, with a simple moving average of 24.09% for the last 200 days.
Analysts’ Opinion of AGIO
Piper Sandler, on the other hand, stated in their research note that they expect to see AGIO reach a price target of $41. The rating they have provided for AGIO stocks is “Overweight” according to the report published on February 03rd, 2023.
Goldman gave a rating of “Neutral” to AGIO, setting the target price at $32 in the report published on November 17th of the previous year.
AGIO Trading at 6.21% from the 50-Day Moving Average
After a stumble in the market that brought AGIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.79% of loss for the given period.
Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares surge +8.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.92% upper at present.
During the last 5 trading sessions, AGIO rose by +7.61%, which changed the moving average for the period of 200-days by +17.95% in comparison to the 20-day moving average, which settled at $29.48. In addition, Agios Pharmaceuticals Inc saw 42.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AGIO starting from FOUSE JACQUALYN A, who sale 7,791 shares at the price of $27.55 back on Apr 10 ’24. After this action, FOUSE JACQUALYN A now owns 137,396 shares of Agios Pharmaceuticals Inc, valued at $214,642 using the latest closing price.
Foster-Cheek Kaye I, the Director of Agios Pharmaceuticals Inc, sale 1,285 shares at $31.62 during a trade that took place back on Mar 07 ’24, which means that Foster-Cheek Kaye I is holding 5,524 shares at $40,632 based on the most recent closing price.
Stock Fundamentals for AGIO
Current profitability levels for the company are sitting at:
- -14.6 for the present operating margin
- 0.84 for the gross margin
The net margin for Agios Pharmaceuticals Inc stands at -12.77. The total capital return value is set at -0.45. Equity return is now at value -36.83, with -32.36 for asset returns.
Based on Agios Pharmaceuticals Inc (AGIO), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -4.11. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 40.8.
Currently, EBITDA for the company is -384.86 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 65.02. The receivables turnover for the company is 9.55for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.27.
Conclusion
In a nutshell, Agios Pharmaceuticals Inc (AGIO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
